GlassScriptPhysician profile
Amy A Walsh
NPI 1790791226
$1,290.52
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $392 · 2021: $157 · 2022: $476.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $261.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $131.39 | 2019-2022 | |
| Amarin Pharma, INC. | $86.28 | 2020 | |
| Bausch Health US, LLC | $83.69 | 2019-2022 | |
| Novo Nordisk INC | $82.64 | 2019-2020 | |
| Astellas Pharma US INC | $76.02 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.17 | 2022 | |
| Amgen INC. | $47.16 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.27 | 2019-2022 | |
| Ibsa Pharma INC. | $45.31 | 2019-2021 | |
| Lilly USA, LLC | $44.62 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $41.28 | 2019-2020 | |
| Allergan, INC. | $30.98 | 2019 | |
| Currax Pharmaceuticals LLC | $28.02 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $25.14 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.33 | 2022 | |
| Esperion Therapeutics, INC. | $20.50 | 2020 | |
| Ironwood Pharmaceuticals, INC | $19.24 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.04 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.65 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.12 | 2020 | |
| Endo Pharmaceuticals INC. | $15.51 | 2020 | |
| Mannkind Corporation | $15.33 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.25 | 2019 | |
| Renalytix Ai, INC. | $12.18 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.